{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:08:30Z","timestamp":1762625310629},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s11882-024-01174-6","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T09:02:49Z","timestamp":1725267769000},"page":"623-629","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["To the ER? Can Patients Treat Their Anaphylaxis at Home?"],"prefix":"10.1007","volume":"24","author":[{"given":"Marcus S.","family":"Shaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Greenhawt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"1174_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.anai.2015.07.019","volume":"115","author":"P Lieberman","year":"2015","unstructured":"Lieberman P, Nicklas RA, Randolph C, Oppenheimer J, Bernstein D, Bernstein J, et al. Anaphylaxis\u2013a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115:341\u201384.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1174_CR2","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jaci.2014.09.014","volume":"135","author":"FE Simons","year":"2015","unstructured":"Simons FE, Sampson HA, Anaphylaxis. Unique aspects of clinical diagnosis and management in infants (birth to age 2 years). J Allergy Clin Immunol. 2015;135:1125\u201331.","journal-title":"J Allergy Clin Immunol"},{"key":"1174_CR3","doi-asserted-by":"crossref","unstructured":"Sicherer SH, Simons FER, Section On A. Immunology. Epinephrine for First-Aid Management of Anaphylaxis. Pediatrics 2017;139.","DOI":"10.1542\/peds.2016-4006"},{"key":"1174_CR4","doi-asserted-by":"crossref","unstructured":"Shaker M, Kanaoka T, Feenan L, Greenhawt M. ** This paper modeled the health and economic outcomes of a universal strategy that all patients who self-inject with epinephrine after a food allergic reaction should activate emergency medical services (EMS) vs. watchful waiting for a lack of medication response before activation, showing universal EMS activation was not cost-effective compared to watchful waiting. Allergy Asthma Immunol. 2019;122:79\u201385. Economic Outcomes of Immediate Activation of Emergency Medical Services After Epinephrine Use for Peanut-induced Anaphylaxis. Ann Allergy Asthma Immunol Ann.","DOI":"10.1016\/j.anai.2018.06.035"},{"key":"1174_CR5","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.jaip.2020.04.022","volume":"8","author":"Casale","year":"2020","unstructured":"Casale TB, Wang J, Nowak-Wegrzyn A. Acute at Home Management of Anaphylaxis during the Covid-19 pandemic. J Allergy Clin Immunol Pract. 2020;8:1795\u20137. This paper, from the stay at home early COVID-19 pandemic phase, implemented the Shaker et al 2019 watchful waiting evidence to revise anapylaxis action plans during COVID-19.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1174_CR6","doi-asserted-by":"crossref","unstructured":"Casale TB, Wang J, Oppenheimer J, Nowak-Wegrzyn A. Acute At-Home Management of Anaphylaxis: 911: What Is the Emergency? J Allergy Clin Immunol Pract 2022;10:2274-9.* This review discusses practical evolutions to at-home management of anaphylaxis which have evolved in recent years.","DOI":"10.1016\/j.jaip.2022.04.040"},{"key":"1174_CR7","unstructured":"Golden DBK, Wang J, Waserman S, Akin C, Campbell RL, Ellis AK, Anaphylaxis et al. A 2023 practice parameter update. Ann Allergy Asthma Immunol 2024;132:124\u2009\u2013\u200976.**This is the most recent practice parameter update, which conditionally recommends a watchful waiting strategy post-epinephrine and outlines the contexts in which this is most appropriate to recommend this to patients."},{"key":"1174_CR8","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaip.2019.11.027","volume":"8","author":"PJ Turner","year":"2020","unstructured":"Turner PJ, Campbell DE, Motosue MS, Campbell RL. Global trends in Anaphylaxis Epidemiology and Clinical implications. J Allergy Clin Immunol Pract. 2020;8:1169\u201376.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1174_CR9","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1111\/cea.12477","volume":"45","author":"T Umasunthar","year":"2015","unstructured":"Umasunthar T, Leonardi-Bee J, Turner PJ, Hodes M, Gore C, Warner JO, et al. Incidence of food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clin Exp Allergy. 2015;45:1621\u201336.","journal-title":"Clin Exp Allergy"},{"key":"1174_CR10","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaip.2017.06.031","volume":"5","author":"PJ Turner","year":"2017","unstructured":"Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal anaphylaxis: Mortality Rate and Risk factors. J Allergy Clin Immunol Pract. 2017;5:1169\u201378.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1174_CR11","unstructured":"https:\/\/injuryfactsnscorg\/motor-vehicle\/historical-fatality-trends\/deaths-and-rates\/#:~:text=The%20population%20motor%2Dvehicle%20death,vehicles%2C%20a%2095%25%20improvement. \"http:\/\/motor-vehicle\/historical-fatality-trends\/deaths-and-rates\/#:~:text=The%20population%20motor%2Dvehicle%20death,vehicles%2C%20a%2095%25%20improvement\" \/> Accessed May 20, 2024."},{"key":"1174_CR12","unstructured":"https:\/\/.wwwbmjcom\/content\/suppl\/2003\/09\/25\/3277417694DC1"},{"key":"1174_CR13","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","volume":"145","author":"MS Shaker","year":"2020","unstructured":"Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of recommendations, Assessment, Development and evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020;145:1082\u2013123.","journal-title":"J Allergy Clin Immunol"},{"key":"1174_CR14","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jaip.2017.07.041","volume":"6","author":"MS Motosue","year":"2018","unstructured":"Motosue MS, Bellolio MF, Van Houten HK, Shah ND, Li JT, Campbell RL. Outcomes of Emergency Department Anaphylaxis visits from 2005 to 2014. J Allergy Clin Immunol Pract. 2018;6:1002\u20139. e2.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1174_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.anai.2023.04.003","volume":"131","author":"M Greenhawt","year":"2023","unstructured":"Greenhawt M. Is epinephrine truly lifesaving, and can we prove this? Ann Allergy Asthma Immunol. 2023;131:279\u201382.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1174_CR16","doi-asserted-by":"crossref","unstructured":"Lieberman JA, Oppenheimer J, Hernandez-Trujillo VP, Blaiss MS. Innovations in the treatment of anaphylaxis: A review of recent data. Ann Allergy Asthma Immunol. 2023;131:185\u2009\u2013\u200993 e10.*. This is a review of more recent data regarding epinephrine pharmacokinetics and pharmacodynamics.","DOI":"10.1016\/j.anai.2023.05.033"},{"key":"1174_CR17","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jaci.2015.11.015","volume":"137","author":"LB Grabenhenrich","year":"2016","unstructured":"Grabenhenrich LB, Dolle S, Moneret-Vautrin A, Kohli A, Lange L, Spindler T, et al. Anaphylaxis in children and adolescents: the European Anaphylaxis Registry. J Allergy Clin Immunol. 2016;137:1128\u2013e371.","journal-title":"J Allergy Clin Immunol"},{"key":"1174_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.anai.2017.06.001","volume":"119","author":"M Robinson","year":"2017","unstructured":"Robinson M, Greenhawt M, Stukus DR. Factors associated with epinephrine administration for anaphylaxis in children before arrival to the emergency department. Ann Allergy Asthma Immunol. 2017;119:164\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1174_CR19","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1542\/peds.2009-2832","volume":"125","author":"SA Rudders","year":"2010","unstructured":"Rudders SA, Banerji A, Corel B, Clark S, Camargo CA. Jr. Multicenter study of repeat epinephrine treatments for food-related anaphylaxis. Pediatrics. 2010;125:e711\u20138.","journal-title":"Pediatrics"},{"key":"1174_CR20","doi-asserted-by":"publisher","first-page":"e1913951","DOI":"10.1001\/jamanetworkopen.2019.13951","volume":"2","author":"M Shaker","year":"2019","unstructured":"Shaker M, Wallace D, Golden DBK, Oppenheimer J, Greenhawt M. Simulation of Health and Economic benefits of Extended Observation of resolved Anaphylaxis. JAMA Netw Open. 2019;2:e1913951.","journal-title":"JAMA Netw Open"},{"key":"1174_CR21","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaip.2023.02.002","volume":"11","author":"TE Dribin","year":"2023","unstructured":"Dribin TE, Waserman S, Turner PJ. Who needs Epinephrine? Anaphylaxis, Autoinjectors, and parachutes. J Allergy Clin Immunol Pract. 2023;11:1036\u201346.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1174_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.anai.2019.05.012","volume":"123","author":"M Shaker","year":"2019","unstructured":"Shaker M, Greenhawt M. A primer on cost-effectiveness in the allergy clinic. Ann Allergy Asthma Immunol. 2019;123:120\u2013e81.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1174_CR23","doi-asserted-by":"crossref","unstructured":"Shaker M, Greenhawt M. The Health and Economic outcomes of Peanut Allergy Management practices. J Allergy Clin Immunol Pract 2018.","DOI":"10.1016\/j.jaip.2018.04.036"},{"key":"1174_CR24","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.jaip.2021.01.007","volume":"9","author":"M Shaker","year":"2021","unstructured":"Shaker M, Turner PJ, Greenhawt MA, Cost-Effectiveness. Analysis of Epinephrine Autoinjector Risk Stratification for patients with Food Allergy-One Epinephrine Autoinjector or two? J Allergy Clin Immunol Pract. 2021;9:2440\u201351. e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1174_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/jamapediatrics.2018.4275","volume":"173","author":"MS Shaker","year":"2019","unstructured":"Shaker MS, Greenhawt MJ. Analysis of Value-based costs of Undesignated School Stock Epinephrine policies for Peanut anaphylaxis. JAMA Pediatr. 2019;173:169\u201375.","journal-title":"JAMA Pediatr"},{"key":"1174_CR26","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.anai.2019.09.009","volume":"123","author":"D Sun","year":"2019","unstructured":"Sun D, Cafone J, Shaker M, Greenhawt M. The cost-effectiveness of requiring universal vs contextual self-injectable epinephrine autoinjector for allergen immunotherapy. Ann Allergy Asthma Immunol. 2019;123:582\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1174_CR27","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.jaip.2020.05.007","volume":"8","author":"MS Shaker","year":"2020","unstructured":"Shaker MS, Mosnaim G, Oppenheimer J, Stukus D, Abrams EM, Greenhawt M. Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select patients with High Health Literacy during the COVID-19 pandemic: a cost-effectiveness analysis during exceptional Times. J Allergy Clin Immunol Pract. 2020;8:2310\u201321. e4.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1174_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaip.2019.09.037","volume":"8","author":"M Shaker","year":"2020","unstructured":"Shaker M, Briggs A, Dbouk A, Dutille E, Oppenheimer J, Greenhawt M. Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab. J Allergy Clin Immunol Pract. 2020;8:565\u201372.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1174_CR29","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/cea.12211","volume":"43","author":"T Umasunthar","year":"2013","unstructured":"Umasunthar T, Leonardi-Bee J, Hodes M, Turner PJ, Gore C, Habibi P, et al. Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clin Exp Allergy. 2013;43:1333\u201341.","journal-title":"Clin Exp Allergy"},{"key":"1174_CR30","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jaip.2019.05.040","volume":"7","author":"LB Grabenhenrich","year":"2019","unstructured":"Grabenhenrich LB, Fernandez-Rivas M, Dolle-Bierke S, Worm M. Repeated epinephrine doses: an analysis of the European Anaphylaxis Registry, 2007\u20132018. J Allergy Clin Immunol Pract. 2019;7:2935\u20137.","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01174-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-024-01174-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-024-01174-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T08:18:30Z","timestamp":1728461910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-024-01174-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1007\/s11882-024-01174-6","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"type":"print","value":"1529-7322"},{"type":"electronic","value":"1534-6315"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"17 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"MS: is a member and co-chair of the Joint Task Force on Practice Parameters, serves on the editorial board of The Journal of Allergy and Clinical Immunology In Practice, is an associate editor of Annals of Allergy, Asthma & Immunology, and serves on the board of directors of the American Academy of Allergy, Asthma& Immunology (views expressed are his own).AA: reports institutional funding (Aimmune, Novartis, FARE), Advisory Board member (DBV Technologies, Novartis, Bryn, Ready, set, food, Genentech), consultation\/speaker fees (ALK, Adelphi, Medscape, Innovation horizons, EPG Health, Genentech, FARE).MG: is a consultant for Aquestive; is a member of physician\/medical advisory boards for DBV Technologies, Takeda, Griffols, Nutricia, Novartis, Aquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, Bryn, Genentech, and Prota; is a speaker for Genentech; is an unpaid member of the scientific advisory council for the National Peanut Board and medical advisory board of the International Food Protein Induced Enterocolitis Syndrome Association; is a member of the Brighton Collaboration Criteria Vaccine Anaphylaxis 2.0 working group; is the senior associate editor for the Annals of Allergy, Asthma, and Immunology, and is member of the Joint Taskforce on Allergy Practice Parameters. He has received honorarium for lectures from ImSci, Red Nucleus, Medscape, Paradigm Medical Communications, Kaplan, Food Allergy Research and Education, and multiple state\/local allergy societies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}